Actively Recruiting
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-05-14
71
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.
CONDITIONS
Official Title
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient is 26 years old or younger at the time of consent
- Diagnosed with high-risk or very high-risk blood cancers including acute myelogenous leukemia, acute lymphoblastic leukemia, other acute leukemias, myelodysplastic syndrome, non-Hodgkin lymphoma, or Hodgkin lymphoma
- No available suitably matched related or unrelated donor within 4 weeks for high-risk disease group
- Meet specific remission and disease status criteria based on leukemia or lymphoma type
- Performance score of at least 70% (Karnofsky or Lansky)
- Not pregnant and not nursing
- Adequate organ function including liver, lung, heart, and kidney function
- Negative pregnancy test for females of childbearing potential within 7 days prior to enrollment
- For very high-risk disease: prior allogeneic transplant at least 4 months ago with disease recurrence or relapsed/refractory disease with less than 30% bone marrow blasts
- Willingness and ability to comply with study procedures and follow-up
You will not qualify if you...
- Inadequate performance status or organ function
- Active central nervous system leukemic involvement
- Presence of chloroma larger than 2 cm
- Active and uncontrolled bacterial, fungal, or viral infection at time of transplant
- HIV infection
- Positive for HTLV-1 virus
- Pregnancy or breastfeeding
- Inability of patient or guardian to provide informed consent or comply with protocol
- Any abnormal condition or lab result that may affect patient safety or study outcome
- For very high-risk disease: allogeneic hematopoietic cell transplant within the past 4 months
- Chronic hepatitis B infection with detectable viral load despite therapy
- Untreated or active hepatitis C infection (patients must be cured or have undetectable viral load if on treatment)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
Research Team
A
Andromachi Scaradavou, MD
CONTACT
J
Jaap Jan Boelens, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here